Day: March 25, 2022

Rematic Tokens LLC [RMTX] launching 501(c)3 non-profit CryptoPositive Inc. and heath wellness business Crypto Positive LLC [CPTX]

WASHINGTON, March 25, 2022 (GLOBE NEWSWIRE) — In January 2022, with a collective passion for philanthropy from the core team of Rematic, the RMTX Chief Hype Officer (CHO) Ricky, aka Ricky Ticky Timbo, started a movement with a tweet. The now CPTX Project Chief Energy Officer (CEO) sparked a vision to create a fully self-sustained charitable crypto project, and two months later, CPO and CPTX were born. The token, CPTX on the Binance Smart Chain, is meant to reward its holders and serve as a contribution source to its non-profit brother, CryptoPositive Inc., a 501(c)3 registered in Delaware. What started as a tweet using the #CryptoPositive back in January of 2022, has transformed into a full-throttle mission to provide goodwill and charity to all in need.

Ricky will assume the role of CEO for Crypto Positive LLC to head the CPTX token project. The first-ever crypto Chief Hype Officer of Rematic will also serve as the Interim CEO for CryptoPositive Inc. Ricky received his BS in Business Administration with an emphasis in Marketing and Finance. He has 20+ years of experience working in multiple industries, including the Aerospace and Medical Device Manufacturing sectors, having worked with prominent names such as Boeing, Northrop Grumman, and Alcoa. With a strong background in operations, international business, negotiation, and marketing, he will be instrumental in creating and executing all strategies that promote positive company growth. Ricky plans to fully dox himself once $1,000,000 in charity is distributed by CPO.

Alongside him will be CPTX COO Raymond Cardenas. Coming from humble beginnings, Ray did not follow the traditional route to success. Working in nearly every industry, finding failure and success, he made his way into sales, excelling quickly, developing, and executing sales and marketing strategies for small-sized SaaS companies. He then transitioned into sales and financing for automotive dealerships.

Crypto Positive LLC (CPTX) and CryptoPositive Inc. (CPO) will both operate under the same beliefs as Rematic Tokens LLC (RMTX), “Business first, token second.” Aiding individuals and fellow non-profits will always be the main focus and, as such, CPO will look to establish a full Board of Directors comprised of crypto project executives and experienced individuals immediately after the launch of $CPTX Token.

Once in place, the bulk structuring of CPO will begin, the goal being to have a fully functioning organization ready to disperse contributions to anywhere in the world to those in need.

“Let’s improve the world, one donation at a time.”

For more info, please get in touch with Raymond Cardenas – COO | ray.cardenas@rematictokens.net

For more info about CryptoPositive LLC, please visit http://cryptopositive.net

For more information about CryptoPositive Inc, please visit http://cryptopositive.org

To engage with the community, please visit the Telegram https://t.me/CryptoPositiveToken

Follow on Twitter https://twitter.com/0xCPTX

Related Images

Image 1: CryptoPositive

Crypto Positive Inc.

This content was issued through the press release distribution service at Newswire.com.

Attachment

• CryptoPositive

HONG KONG, March 25, 2022 (GLOBE NEWSWIRE) — ProcureNet’s Humanitarian Aid division announced significant commitments to provide urgent support to Ukraine citizens impacted by the conflict.

ProcureNets Humanitarian Aid division is honored to be providing its support to Doctors without Borders. The Company is providing 10,000 thermal blankets to Doctors Without Borders to support their relief efforts to thousands of families fleeing spiraling violence as Ukraine still fights one of its coldest winters.

“We have been moved and inspired by the courage of Ukrainian families, and we are proud to be offering our support in their time of need through our Emergency Humanitarian Response Center,” said Chahal.

The Humanitarian Aid Division shares the same core values as shown in Medriva’s #onebillionstrong viral campaign, which has aided over 1 billion vaccinations through the supply of vaccine consumables such as WHO-approved auto-disabled syringes.

“We are honored to support Doctors Without Borders and look forward to collaborating with them further as they work to deliver relief to displaced citizens and their families who have had to flee their homes. ProcureNet’s initial support of supplies will be the start of many to come as we look to allocate more resources to Ukraine,” said ProcureNet chief executive and founder Gurbaksh Chahal.

Doctors Without Borders/Medecins Sans Frontieres (MSF) has been stepping up its humanitarian response to the deepening humanitarian crisis in Ukraine and neighboring countries, where more than 3 million refugees have fled.

MSF has a longstanding presence in Ukraine, including in regions of eastern Ukraine that have been affected by armed conflict since 2014. They currently have teams in Ukraine, Poland, Moldova, Hungary, Slovakia, Russia, and Belarus.

As an independent and impartial organization, MSF is committed to providing medical humanitarian assistance to people affected by the war, no matter who they are or where they are. Since the fighting spread across the country, their teams have been working around the clock to respond to urgent medical humanitarian needs and racing to get the proper medical supplies to the right places.

ProcureNet has been at the forefront of providing medical relief and protective equipment globally to governments and NGOs during various disaster relief efforts, working with national governments and international organizations such as WHO, UNICEF and PAHO.

As a leading global leader of pharmaceutical materials and vaccines consumables, ProcureNet connects government authorities, international organizations and large businesses to a vast network of pre-approved on-demand manufacturers that produce the world’s most sought-after commodities at rapid speed and tremendous scale.

ProcureNet’s Humanitarian Aid division delivers emergency medicine, protective supplies, medical devices, and protective wear as aid to developing nations, NGOs, and partners worldwide. To learn more information please visit: procure-net.com/humanitarianaid

Press Contact: 

Euan Humphreys: euan.humphreys@procure-net.com

Related Images

Image 1: ProcureNet Cargo

ProcureNet Thermal Blankets being delivered to Ukraine

This content was issued through the press release distribution service at Newswire.com.

Attachment

• ProcureNet Cargo

HERMOSILLO, Mexico, March 24, 2022 (GLOBE NEWSWIRE) — AM FRESH Group and RIO BLANCO combine forces to establish TERRAMARA FRESH, a joint venture powerhouse of innovative table grape varieties and sustainable farming. For over 30 years, RIO BLANCO – through its TERRAMARA investment – has thrived as a competitive farming platform. The new combined partnership will focus on production of a diverse array of premium varieties, to offer customers a breadth of high-flavored, disease resistant, and high-antioxidant table grape varieties. The premium varieties from proprietary breeding platforms will complement the existing table grape offer, improve competitiveness of table grapes relative to other fruits, and ultimately drive the sophistication of the table grape category for the benefit of retailers and consumers.

The emphasis on production will focus on innovative grapes which are resilient, have higher yields, are more resistant to weather changes, deliver consistent high-quality flavor profiles and have higher nutritional values aims to propel farming in Mexico and continue to expand in coming years. The combined agri-tech and farming expertise of AM FRESH and RIO BLANCO will accelerate farming innovation to the forefront of fruit growing practices.

“At AM FRESH we seek to deliver the next generation of innovative table grape varieties and together with RIO BLANCO we have the thrilling opportunity to excite consumers with delicious, healthy and natural varieties produced under sustainable practices, as well as to extend the growing season to meet growing demand,” said Alvaro Muñoz, CEO of AM FRESH Group.

“Sustainable agriculture is pivotal for RIO BLANCO and the region in which we operate,” said Sandro Peppi, Chairman of RIO BLANCO. “In order to drive significant impact in the table grape industry in Mexico and to our export markets, it is critical that we combine our efforts with global grape experts and together accelerate a more sustainable future for Mexico and the table grape category.”

The new combined entity will be managed by Luis Felipe Montes, Managing Director of TERRAMARA for the past nine years. Luis Felipe stated, “We are thrilled by this joint venture and its objective to add growth, cooperation and new technology to TERRAMARA in the development of new varieties and therefore get closer to retailers and consumers.”

AM FRESH Group is focused on leading varietal innovation, agrotechnology and biotechnology, extensive agriculture and global marketing of citrus, table grapes, tropical products and superfoods, plant-based foods, apples and pears and flowers. AM FRESH is a family business with more than 90 years of experience, present in more than 60 countries and with more than 6,200 employees who are passionate and committed to innovation. AM FRESH operates with an integrated value chain model to serve major retailers around the world. For more information visit www.amfresh.com

The RIO BLANCO Group is a family business, a leader in its field, established in the late 1970s. Its founders are pioneers in the fruit industry based in Chile, with constant growth and are proud to have a reputable brand and quality products recognized worldwide. RIO BLANCO develops sustainable cultivation through state-of-the-art technology, with operations in Hermosillo, Mexico and in the main area from Curicó to Copiapó in Chile, in addition to currently incorporating new areas of operation in Mexico, predominantly of table grapes, citrus, pomegranates, kiwis and cherries. RIO BLANCO is supported by a fully integrated value chain that includes production, processing, shipping and distribution of fresh fruit and a group of experts in the field that make up the core of its human resources. For more information visit www.rioblanco.net

Patricia Sagarminaga
AM FRESH Group
Group Director Marketing & Communications patricia.sagarminaga@amfresh.com +34669161941

REGULATED INFORMATION 

Nyxoah Reports Full Year 2021 Operating and Financial Results

Mont-Saint-Guibert, Belgium – March 24, 2022, 9:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the full year ending December 31, 2021.

Full Year 2021 Operational and Financial Highlights

•  Generated revenue of €852,000 from the commercialization of Genio® in Europe, mainly in Germany; gross margin was 64.4%
•  Achieved strong commercial progress in Germany after obtaining a DRG code for the Genio system
•  Obtained DRG coding in Switzerland and hospital reimbursement in Spain; awaiting reimbursement decisions in other key European markets
•  Reported positive data from the BETTER SLEEP clinical trial, which achieved its primary safety and performance endpoints, with statistically significant reduction in baseline AHI scores for the overall study and the complete concentric collapse (CCC) and non-CCC patient cohorts; per the Sher criteria, after 6 months, achieved responder rates of 64% for the entire population (CCC and non-CCC), 60% for the CCC cohort, and 67% for the non-CCC cohort
•  Received expanded CE mark indication to treat CCC patients, thus increasing the total addressable market by at least 30% and enabling patients not to have to undergo a Drug-Induced Sleep Endoscopy (DISE) procedure prior to implantation
•  Granted U.S. FDA Breakthrough Device Designation for the treatment of adult patients with moderate-to-severe OSA and CCC; awaiting IDE approval to commence a trial for CCC patients in the U.S. in late 2022
•  Advanced patient enrollment in the DREAM U.S. IDE study, with implants expected to be completed in the second quarter of 2022
•  Raised $97.8 million in a Nasdaq initial public offering in July, successfully completing Nyxoah’s second IPO after previously raising €84.8 million in the September 2020 Euronext Brussels IPO
•  Entered exclusive licensing agreement with Vanderbilt University (US) to develop next generation neurostimulation technologies, specifically a novel stimulator focused on the Ansa Cervicalis nerve, which could further expand the eligible to treat OSA patient population.

“2021 was a very strong year for Nyxoah. I am proud of the team maintaining their focus on execution while operating in a challenging market environment. We reached numerous milestones in 2021 and feel we are well positioned to further build on this momentum in 2022,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “Through the BETTER SLEEP study results, we are now able to offer an effective solution for CCC patients with an expanded CE mark indication in Europe, and we are working hard to initiate a CCC-focused IDE trial in the US. Particularly encouraging are the strong responder rates in all patient cohorts, further increasing our confidence in positive outcomes from the ongoing DREAM study.”

“We have also been happy with our commercial progress in Europe, focusing on Germany, where we obtained a dedicated DRG code.” continued Mr. Taelman. “We already had 12 active implant sites in December 2021 and continue to expand rapidly. In addition, we have secured a DRG code in Switzerland and hospital reimbursement in Spain while we await final reimbursement decisions in the Netherlands and Belgium. Our commercial strategy is based on a deep understanding of the patient journey, building strong relationships with implanting surgeons and further strengthening their relationships with referring sleep physicians, in combination with digital marketing programs.”

Mr. Taelman continued, “We secured CE mark MR conditional labeling for Genio®, enabling all implanted patients to safely undergo 1.5T and 3T MRI diagnostics scans. Genio® is now the only HGNS device with an MRI compatibility label for full-body and 3T. This illustrates our patient-centric strategy, and you can soon expect to hear more on the progress made by our R&D team. Short term, we expect to launch the next generation Genio® 2.1, which includes a patient-centric smartphone app and will incorporate a position sensor to adjust stimulation levels based on sleeping position. Looking further into the future, we are proud of our collaboration with Vanderbilt University and Dr. Kent that should result in novel treatment options for OSA patients, starting with Ansa Cervicalis stimulation.”

“With our second successful IPO in the span of 10 months last July, we have a strong balance sheet that provides ample liquidity to complete the DREAM study, conduct our U.S. CCC IDE study, invest in pre-commercial activities in the U.S., and remain committed to our important R&D priorities. We are extremely excited about where we are today as a company, and we look forward to providing further updates as the year progresses,” concluded Mr. Taelman.

 

 Full Year 2021 Results

CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (in thousands)

				For the year ended December 31
				2021		2020
Revenue				€  852		€  69
Cost of goods sold				(303)		(30)
Gross profit				€  549		€  39
General and administrative expenses				(11 113)		(7 522)
Research and development expenses				(2 353)		(473)
Clinical expenses				(2 706)		(1 053)
Manufacturing expenses				(4 760)		(460)
Quality assurance and regulatory expenses				(1 463)		(227)
Patents fees & Related				(1 062)		(123)
Therapy development expenses				(3 599)		(1 864)
Other operating income / (expenses)				265		459
Operating loss for the period				€ (26 242)		€ (11 224)
Financial income				3 675		62
Financial expense				(2 072)		(990)
Loss for the period before taxes				€ (24 639)		€ (12 152)
Income taxes				(2 980)		(93)
Loss for the period				€ (27 619)		€ (12 245)
Loss attributable to equity holders				€ (27 619)		€ (12 245)
Other comprehensive income/(loss)
Items that may not be subsequently reclassified to profit or loss (net of tax)
Remeasurements of post-employment benefit obligations, net of tax				(68)		−
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences				121		(58)
Total other comprehensive income/(loss)				€  53		€ (58)
Total comprehensive loss for the year, net of tax				€ (27 566)		€ (12 303)
Loss attributable to equity holders				€ (27 566)		€ (12 303)
Basic loss per share (in EUR)				€ (1.161)		€ (0.677)
Diluted loss per share (in EUR)				€ (1.161)		€ (0.677)

 

CONSOLIDATED BALANCE SHEETS (in thousands)

				As at December 31
				2021		2020
ASSETS
Non-current assets
Property, plant and equipment				€ 2 020		€  713
Intangible assets				25 322		15 853
Right of use assets				3 218		3 283
Deferred tax asset				46		32
Other long-term receivables				164		91
				€ 30 770		€ 19 972
Current assets
Inventory				346		55
Trade receivables				226		−
Other receivables				2 286		1 644
Other current assets				1 693		109
Cash and cash equivalents				135 509		92 300
				€ 140 060		€ 94 108
Total assets				€ 170 830		€ 114 080
EQUITY AND LIABILITIES
Capital and reserves
Capital				4 427		3 796
Share premium				228 033		150 936
Share based payment reserve				3 127		2 650
Other comprehensive income				202		149
Retained loss				(87 167)		(60 341)
Total equity attributable to shareholders				€ 148 622		€ 97 190
LIABILITIES
Non-current liabilities
Financial debt				7 802		7 607
Lease liability				2 737		2 844
Pension liability				80		37
Provisions				12		−
Deferred tax liability				5		−
				€ 10 636		€ 10 488
Current liabilities
Financial debt				554		616
Lease liability				582		473
Trade payables				3 995		1 190
Current tax liability				2 808		−
Other payables				3 633		4 123
				€ 11 572		€ 6 402
Total liabilities				€ 22 208		€ 16 890
Total equity and liabilities				€ 170 830		€ 114 080

Revenue

Revenue was €852,000 for the twelve months ending December 31, 2021, compared to €69,000 for the twelve months ending December 31, 2020. The increase in revenue was attributable to the Company’s commercialization of the Genio® system, primarily in Germany. Revenue for the second half of 2021 was €497,000, a 40.0% increase versus the first half of the year despite COVID-related headwinds during the fourth quarter.

Cost of Goods Sold

Cost of goods sold was €303,000 for the twelve months ending December 31, 2021, representing a gross profit of €549,000, or gross margin of 64.4%. This compares to total costs of goods sold of €30,000 in the 2020, for a gross profit of €39,000, or gross margin of 56.5%.

General and Administrative Expenses

General and administrative expenses rose to €11.1 million for the full year ending December 31, 2021, from €7.5 million in the prior year. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah’s corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of U.S. commercial launch.

Research and Development Expenses

Research and Development expenses were €2.4 million for the twelve months ending December 31, 2021, a substantial increase over the €0.5 million for the prior year, reflecting the ongoing research and development activities, most notably the development of next generation versions of the Genio® system. As of January 2021, the Company started to amortize its intangible assets, which explains the significant increase in depreciation expenses for the twelve months ending December 31, 2021, compared to the twelve months ending December 31, 2020.

Clinical Expenses

Clinical expenses increased to €2.7 million for the twelve months ending December 31, 2021, from €1.1 million for the twelve months ending December 31, 2020. Total clinical expenses were €9.5 million, of which €6.8 million was capitalized, reflecting an increase in staff and consulting to support the completion of the BETTER SLEEP trial implantations, continuous recruitment for the EliSA trial, and the ongoing DREAM IDE trial in the United States.

Manufacturing Expenses 

Manufacturing expenses increased to €4.8 million for the twelve months ending December 31, 2021, from €0.5 million for the twelve months ending December 30, 2020, due mainly to increased demand for our Genio^® system for both commercial and non-commercial purposes.

Quality Assurance and Regulatory Expenses

Quality assurance and regulatory expenses of €1.5 million for the year ending December 31, 2021, were up significantly from €0.2 million for the year ending December 31, 2020, to support the scale-up of operations.

Patent Fees & Related Expenses

Patents fees and related expenses increased from €0.1 million for the twelve months ending December 31, 2020, to €1.1 million for the twelve months ending December 31, 2021, due to expenses related to the exclusive licensing agreement with Vanderbilt University.

Therapy Development Expenses

Therapy development expenses were €3.6 million for the twelve months ending December 31, 2021, versus €1.9 million for the twelve months ending December 31, 2020. The increase in expenses was mainly driven by the scale-up of commercial operations in Europe.

Operating Loss

The Company realized a net loss of €27.6 million for the full year ending December 31, 2021, compared to a net loss of €12.2 million for the full year ending December 31, 2020, due to increases of activities in all departments.

Cash Position

Cash and cash equivalents totaled €135.5 million on December 31, 2021, as compared to €92.3 million on December 31, 2020.  The increase was due primarily to total gross proceeds of $97.8 million generated from the July 2021 IPO.

Net cash used in operations was €25.3 million for the twelve months ending December 31, 2021, compared to €6.9 million for the twelve months ending December 31, 2020. The increase was primarily due to an increase in net loss for the period that was mainly attributable to increased general and administrative expenses, research and development expenses, manufacturing expenses and therapy development expenses, which were offset by a positive variation in the working capital of €1.1 million.

Net cash used in investing activities was €11.8 million for the twelve months ending December 31, 2021, compared €10.7 million for the twelve months ending December 31, 2020.

Net cash generated in financing activities for the twelve months ending December 31, 2021, was €76.5 compared to €104.0 million of net cash provided by financing activities during the twelve months ending December 31, 2020.

Outlook for 2022

The Company’s business, operational, and clinical outlook for 2022 include the following expected milestones and goals:

•  Completing DREAM trial implants in the second quarter of 2022
•  Continuing commercial execution in Germany
•  Commencing a U.S. IDE study for CCC patients in the fourth quarter of 2022

Full-year report 2021
Nyxoah’s financial report for the full year 2021, including details of the audited consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation 
Nyxoah will conduct a conference call to open to the public tomorrow, March 25, 2022, at 1:00 p.m. CET / 8:00 a.m. ET, which will also be webcasted. To participate in the conference call, please dial one of the following numbers:

Conference ID: 3688760

USA:                             (844) 260-3718
Belgium:                       0800 73264
International:                (929) 517-0938

A question-and-answer session will follow the presentation of the results. To access the live webcast, go to https://investors.nyxoah.com/events. The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements 
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, to be filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment

• ENGLISH_FY 2021 Earnings PR – FINAL

Australian mortgage lender completes digital transformation with robust, end-to-end platform

SYDNEY, Australia, March 24, 2022 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking and digital transformation solutions for the global financial services industry, today announced that RedZed, an Australian mortgage company for the self-employed, is live on the nCino Bank Operating System®. RedZed selected PwC Australia as their delivery partner, who in conjunction with the nCino team in Australia, were able to transform RedZed’s mortgage lending process and go live on nCino’s Mortgage Solution.

With a growing customer base, RedZed sought a solution that would enable them to automate and standardise their residential mortgage origination process to accommodate an increase in demand while continuing to deliver a flexible and personalised customer-first experience. The financial services company selected nCino and its Mortgage Solution – an integrated solution that spans the entire origination lifecycle, from multi-channel application and pre-approvals through underwriting, offers and closing – to increase automation, improve loan volume, and decrease the cost of writing new loans.

“nCino’s Mortgage Solution exceeded the expectations of everyone in our organisation and will provide our borrowers and lenders with a personalised and integrated experience that is seamless, transparent and simple,” said Stephen Gorman, Chief Credit Risk Officer at RedZed. “With teams from nCino and PwC collaborating across the globe, the implementation process was smooth and efficient. The dependability of both teams led to the phenomenal success of this project.”

The nCino Mortgage Solution provides RedZed with tools to maintain compliance with the National Consumer Credit Protection Act 2009 (NCCP), including Document Manager, form generation, smart checklist, questionnaires, serviceability calculator, and offers and product matrix. These features will help RedZed achieve operational excellence and manage the entire client portfolio with ease, while also connecting RedZed’s front and back-office to enable them to grow more cost effectively and maximize their digital investments.

“nCino is committed to providing a flexible and adaptable platform that enables financial institutions to deliver change at speed,” said Mark Bernhardi, Managing Director of Australia and New Zealand at nCino. “We are proud to partner with RedZed on their digital transformation journey and help them provide a seamless experience for their brokers and customers. Our relationship with RedZed and PwC embodies our mission to transform the financial services industry through innovation, reputation and speed.”

PwC Australia worked closely with the nCino team, embedding the firm’s BXT – business, eXperience, technology – method to put innovation and experience at the core of the project delivery. By leveraging an agile delivery approach, the project team was able to deploy an end-to-end solution quickly, despite most of the work being completed remotely due to the COVID pandemic.

“This project was successful due to the commitment and initiative shown by all three teams,” added Marvin Slocombe, Engagement Lead at PwC. “Strong relationships, innovation and collaboration allowed us to deliver this project with agility and determination. We are thrilled that RedZed selected PwC to integrate nCino’s Mortgage Solution. We look forward to our continued work together to support RedZed to deliver seamless, personalised services and experience to their customers.”

About nCino
nCino (NASDAQ: NCNO) is the worldwide leader in cloud banking. The nCino Bank Operating System® empowers financial institutions with scalable technology to help them achieve revenue growth, greater efficiency, cost savings and regulatory compliance. In a digital-first world, nCino enhances the employee and client experience to enable financial institutions to more effectively onboard clients, make loans and manage the entire loan life cycle, and open deposit and other accounts across lines of business and channels. Transforming how financial institutions operate through innovation, reputation and speed, nCino is partnered with more than 1,500 financial institutions of all types and sizes on a global basis. For more information, visit: www.ncino.com.

About RedZed
RedZed provides simple to understand residential and commercial mortgage solutions for the 2.1 million Australians that are self-employed. RedZed’s product offering is backed by 48-hour turnaround times, a common-sense approach to underwriting, direct access to credit decision makers that understand the nuances of self-employed lending and are prepared to workshop applications with their accredited brokers. For more information, visit www.redzed.com.

About PwC Australia
At PwC Australia, our purpose is to build trust in society and solve important problems. PwC is a network of firms in 155 countries with over 284,000 people who are committed to delivering quality in assurance, advisory and tax services. Find out more and tell us what matters to you by visiting us at www.pwc.com.au

Media Contacts
North America
Sutton Resler
+1 571.236.4966                  
sresler@mww.com

APAC
Catalina Garcia, nCino
+61 418 215 423
catalina.garcia@ncino.com

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally include actions, events, results, strategies and expectations and are often identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might,” or “continues” or similar expressions. Any forward-looking statements contained in this press release are based upon nCino’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent nCino’s expectations as of the date of this press release.  Subsequent events may cause these expectations to change and, except as may be required by law, nCino does not undertake any obligation to update or revise these forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially including, among others, risks and uncertainties relating to the market adoption of our solution and privacy and data security matters. Additional risks and uncertainties that could affect nCino’s business and financial results are included in reports filed by nCino with the U.S. Securities and Exchange Commission (available on our web site at www.ncino.com or the SEC’s web site at www.sec.gov). Further information on potential risks that could affect actual results will be included in other filings nCino makes with the SEC from time to time.

Pharmaprojects’ 2022 Report Highlights Breakthrough Trends in Pharmaceutical R&D

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) — Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, today announced the launch of its 30^th Edition Pharma R&D Annual Review. The 2022 report assesses industry trends by examining the pharmaceutical pipeline by company, therapeutic area, disease, target, and drug type, using data from Pharma Intelligence’s Pharmaprojects, part of the Citeline suite of products, which has been tracking global drug development since 1980.

The 55-page free report features a travel theme and includes a full analysis and breakdown of 2021 and what to expect for the year ahead. Notable findings include:

• The Drug Pipeline is at an All-time High – The total number of drugs in the pipeline exceeds 20,000, with an annual growth rate of 8.22% and 1,527 new drugs.
• Top Companies and New Players – Once again, Novartis has the largest drug pipeline, followed by Roche. Two Chinese companies, Jiangsu Hengrui and Shanghai Fosun, enter the Top 25 companies by pipeline size for the first time as total number of companies involved in R&D hits 5,416 — a new high.
• COVID-19 and Rare Diseases a Major Focus – Pfizer has the biggest pipeline against COVID-19, but rare diseases continue to dominate pharma’s focus. Novartis has 64.8% of its pipeline targeting rare diseases, the highest of any top 10 pharma, with Lilly the lowest, at 28.2%. Plus, 677 individual rare diseases are the subject of current drug R&D.
• Cancer Drugs, Cell and Gene Therapies Are Booming – Cancer drugs now account for 39% of the pharma pipeline. Cell and gene therapies continue to boom, with almost 2,000 examples of each. AAV is the most used viral vector for gene therapy and T-cells the most popular for cell therapy.
• The Rise of CAR-T and Immuno-oncology – CD3e is now the most popular drug target, followed by CD274 (PD-L1).
• Turbocharged R&D Innovation – An astounding 131 new drug targets were identified during 2021.

For the past 30 years, Ian Lloyd, Senior Director, Pharmaprojects & Data Integration, has authored this must-have industry report for those seeking to identify the changing fortunes of drug R&D. To celebrate this milestone, Lloyd has shared five key insights from past R&D reviews that have come to fruition or are still trending today.

• “We predicted mega-merger mania would be full swing at the turn of the millennium, with four newly merged companies debuting in the Top 25 companies of 2000. We also expected to see large numbers of discontinuations over the coming year as they rationalized their post-merger pipelines.” [2000 Pharma R&D Report]
• “Gene therapy as a therapeutic category plummeted from its 2002 peak as the third most popular class to number 15 by 2004 after widely publicized problems with the groundbreaking SCID-XI gene therapy trials which sent a shockwave through the industry. But we anticipated it would make a spectacular recovery.” [2004 Pharma R&D Report]
• “Sovaldi (sofosbuvir), Gilead’s first-in-class small molecule for hepatitis-C, was in our list of novel NASs from 2013. We noted that it looked like this decade would be the one where a paradigm shift occurs in HCV therapy.” [2014 NAS Supplement to Pharma R&D Report]
• “Immuno-oncology entered our Top 25 of mechanism action in its first year at number two after we had spotted that a new kind of cancer drug, one which primed the body’s own defenses to find cancer, was causing ripples.” [2016 Pharma R&D Report]
• “Over 1,000 new drugs were reported in response to the first year of COVID-19 as we created three new indications in response to emerging pandemic, covering drugs treating the infection itself, agents designed to prevent infection or disease, and drugs to treat COVID-19 complications.” [2021 Pharma R&D Report]

For more information, or to view the current and past reports, visit Informa Pharma Intelligence or contact pharma@informa.com.

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products — Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Biomedtracker™, Scrip™, Pink Sheet™ and In Vivo™ — to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information, visit pharmaintelligence.informa.com

Media Contacts
Diffusion PR for Informa Pharma Intelligence
informapharma@diffusionpr.com